Osmolex ER (Amantadine HCl) Patent Expiration, LOE Window & CMS Spending

Osmolex ER (Amantadine HCl) by Supernus/Adamas: FDA Orange Book LOE 2038-02-15, 16 AB generics, $345K 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSupernus/Adamas
FDA Application & PathwayN209410 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2038-02-15
Orange Book Patents (*PED Extensions)9 patents (0 *PED)
Active AB-Rated Generic Competitors16
2024 CMS Total Public Spend$345K
2024 Medicare Part D Spend$328K
2024 Medicaid Spend$16K
Reported Wholesale Price Change (CA SB 17)4 WAC filings (max 32.7% 2-yr change)